Transplant Trial Watch

• Published in: Transplant international Vol. 36; p. 11202
• Main Author: O’Callaghan, John Matthew
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media SA 21.03.2023; Frontiers Media S.A
• Subjects: Acids; Antibodies; Conflicts of interest; COVID-19; COVID-19 vaccines; Data analysis; Health Archive; Humans; Immune response; Immune response (humoral); Immune system; Immunosuppressive agents; Kidney transplantation; Kidney transplants; mRNA vaccines; Mycophenolate mofetil; Mycophenolic acid; Patients; Pilot projects; Prednisolone; R&D; Rapamycin; Research & development; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Tacrolimus; TOR protein; Transplant Recipients; Transplants; Vectors (Biology); Netherlands; COVID-19; kidney transplant; randomised controlled trial; vaccine; immune response
• ISSN: 1432-2277; 0934-0874; 1432-2277
• DOI: 10.3389/ti.2023.11202

Aims The aim of this study was to compare the immune response to the booster dose of BNT162b2 in renal transplant patients who remain on the standard immunosuppressive regimen [tacrolimus (TAC), MPA, and prednisolone] versus those who switch to the mammalian target of rapamycin inhibitor (mTORi), TAC, and prednisolone regimen. [...]a strategy to improve vaccine response is critical. Statements Conflict of interest The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. 1. de Boer SE Berger SP van Leer-Buter CC Kroesen BJ van Baarle D Sanders JF et al Enhanced Humoral Immune Response after COVID-19 Vaccination in Elderly Kidney Transplant Recipients on Everolimus versus Mycophenolate Mofetil-Containing Immunosuppressive Regimens.